CERo Therapeutics Announces Listing on OTC Markets
CERo Therapeutics (OTC: CERO) confirmed its shares continue trading under the OTC PINK market, effective at market open on October 31, 2025, with no action required from investors.
The company said it is evaluating up-list options to improve liquidity and accessibility while maintaining full operations and staffing. CERo highlighted progress in its Phase 1 AML program for CER-1236, announcing initiation of Cohort 2 and an FDA-approved significant dosage increase for that cohort.
CERo Therapeutics (OTC: CERO) ha confermato che le sue azioni continuano a essere negoziate sul mercato OTC PINK, con effetto all'apertura del mercato il 31 ottobre 2025, senza alcuna azione richiesta dagli investitori.
L'azienda ha dichiarato che sta valutando opzioni di up-listing per migliorare liquidità e accessibilità mantenendo piena operatività e personale. CERo ha evidenziato progressi nel suo programma AML di Fase 1 per il CER-1236, annunciando l'inizio della Cohort 2 e un significativo aumento della dose approvato dalla FDA per quella coorte.
CERO Therapeutics (OTC: CERO) confirmó que sus acciones siguen cotizando en el mercado OTC PINK, con efecto desde la apertura del mercado el 31 de octubre de 2025, sin acción alguna requerida por los inversores.
La compañía dijo que está evaluando opciones de up-list para mejorar la liquidez y la accesibilidad, manteniendo todas las operaciones y el personal. CERo destacó avances en su programa AML de Fase 1 para el CER-1236, anunciando el inicio de la Cohort 2 y un incremento de dosis significativo aprobado por la FDA para esa cohorte.
CERo Therapeutics (OTC: CERO)은 시장 개장일인 2025년 10월 31일에 OTC PINK 시장에서 주식 거래가 계속되며 투자자의 별도 조치가 필요하지 않다고 확인했습니다.
회사는 유동성과 접근성을 개선하기 위한 상장 상향 옵션을 검토 중이며, 전체 운영 및 직원 규모를 유지한다고 밝혔습니다. CERo는 CER-1236의 1상 AML 프로그램의 진전을 강조하며 Cohort 2의 시작과 해당 코호트에 대한 FDA 승인된 용량 증가를 발표했습니다.
CERo Therapeutics (OTC: CERO) a confirmé que ses actions restent négociées sur le marché OTC PINK, à compter de l’ouverture du marché le 31 octobre 2025, sans action requise de la part des investisseurs.
La société a déclaré qu’elle envisage des options de montée en cotation pour améliorer la liquidité et l’accessibilité tout en maintenant l’exploitation et le personnel au complet. CERo a mis en évidence les progrès de son programme AML de phase 1 pour le CER-1236, annonçant l’initiation de la Cohort 2 et une augmentation de dose significative approuvée par la FDA pour cette cohorte.
CERo Therapeutics (OTC: CERO) bestätigte, dass seine Aktien ab dem Market Open am 31. Oktober 2025 weiterhin im OTC PINK-Markt gehandelt werden, ohne dass von Investoren Maßnahmen erforderlich sind.
Das Unternehmen teilte mit, dass es Optionen für eine Up-List in Erwägung zieht, um Liquidität und Zugänglichkeit zu verbessern, während der volle Betrieb und das Personal aufrechterhalten werden. CERo hob Fortschritte in seinem Phase-1- AML-Programm für CER-1236 hervor, kündigte den Start der Kohorte 2 an und eine von der FDA genehmigte signifikante Dosiserhöhung für diese Kohorte.
CERo Therapeutics (OTC: CERO) أكدت أن أسهمها ستظل متداولة ضمن سوق OTC PINK، مع افتتاح السوق بتاريخ 31 أكتوبر 2025، دون حاجة لاتخاذ إجراء من المستثمرين.
قالت الشركة إنها تقيّم خيارات الإدراج لصعود القائمة لتحسين السيولة وإمكانية الوصول مع الحفاظ على عمليات التشغيل والكوادر كاملة. أبرزت CERo التقدم في برنامجها لعلاج AML من المرحلة 1 لـ CER-1236، معلنة بدء Cohort 2 وزيادة جرعة كبيرة معتمدة من FDA لهذه المجموعة.
- Phase 1 Cohort 2 for CER-1236 initiated
- FDA approved a significant dosage increase for Cohort 2
- Shares continue trading under ticker CERO on OTC PINK since Oct 31, 2025
- Trading moved to OTC PINK, which can limit liquidity and visibility compared with major exchanges
Company’s Shares Will Continue to Trade Under Ticker CERO on the OTC Markets
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTC PINK: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company developing novel T cell therapeutics that incorporate phagocytic mechanisms, announces its shares continue to be listed on the public markets under the ticker symbol CERO. Effective as of market open on Friday, October 31, 2025, the Company is listed under the OTC PINK with no action needed on the part of investors. In the meantime, CERo is actively evaluating options for up-list, including, but not limited to another OTC market or another major exchange to optimize liquidity and investor accessibility.
CERo CEO Chris Ehrlich stated, “While our trading market has changed, we want to ensure investors that we are very much open for business as usual and remain committed to maximizing value for our shareholders by continuing to conduct our science and execute on our long-term business strategy. We remain focused on the actions we have taken to advance our current cohort of CER-1236, which includes our recently announced initiation of Cohort 2 in our Phase 1 clinical trial in AML, where dosage is being increased significantly as proposed to and approved by the FDA. In the meantime, we maintain our full operations with all employees and consultants to the Company remaining committed to the objective of developing CER-1236. On behalf of the CERo team, I’d like to extend our collective gratitude for the ongoing commitment and trust of our shareholders and supporters.”
About CERo Therapeutics Holdings, Inc.
CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering integrates key functional attributes of both innate and adaptive immunity within a single therapeutic construct, designed to engage the body’s immune repertoire for more comprehensive tumor targeting. This novel cellular immunotherapy platform is designed to redirect patient-derived T cells toward tumor cells through both adaptive perforin/granzyme pathways and innate engulfment mechanisms. The latter employ phagocytic activity to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells (“CER-T”). CERo believes the differentiated targeting properties of CER-T cells may offer advantages compared with currently approved CAR-T therapies and could potentially extend the reach of cellular immunotherapy to both hematologic malignancies and solid tumors. CERo has initiated clinical trials for its lead product candidate, CER-1236, for hematologic malignancies.
Forward-Looking Statements
This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo’s management.
Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and the documents incorporated by reference therein. The risks described in CERo’s filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Chris Ehrlich
Chief Executive Officer
chris@cero.bio
Investors:
CORE IR
investors@cero.bio
FAQ
What happened to CERo stock (CERO) on October 31, 2025?
Will CERo (CERO) pursue listing on a major exchange or different OTC tier?
What clinical progress did CERo announce for CER-1236 on November 3, 2025?
Do CERo employees and operations remain active after the listing change?
Does the OTC PINK listing require any action from CERO shareholders?
How might the OTC PINK listing affect CERo shareholders in the near term?
